Vistagen Therapeutics VTGN
NASDAQ VTGN
$0.19 -0.01 (-5.00%)
At close: Nov 19, 2026 · 4:00 PM EST

Vistagen Therapeutics (VTGN) Return on Sales [ROS] (2010 - 2026)

Updated

Vistagen Therapeutics (VTGN) reported Return on Sales [ROS] of -7925.36% for fiscal Q2 2027 (quarter ended Sep 30, 2026), down 152.88 percentage points from -7772.48% a year earlier and down 7021.03 percentage points from the prior quarter.

Analysis

Vistagen Therapeutics (VTGN) Return on Sales [ROS] (2010 - 2026) Analysis & Trends

Over the twelve months ended Sep 30, 2026, Vistagen Therapeutics' Return on Sales [ROS] came in at -2541.90%, up 6538.82 percentage points year-over-year; for FY2026 (ended Mar 31, 2026), it was -5683.69%, up 5833.39 percentage points from FY2025.

  • Return on Sales [ROS] has a five-year change of -4037.63 percentage points (FY2021 to FY2026).
  • By fiscal year, Return on Sales [ROS] came in at -11517.08% in FY2025 (-8413.60 pp), -3103.48% in FY2024 (+23005.77 pp), -26109.25% in FY2023 (-21800.96 pp) and -4308.30% in FY2022 (-2662.24 pp).
  • The fiscal Q2 2027 figure ranks as the lowest quarterly Return on Sales [ROS] since fiscal Q4 2025.
  • Year over year, Return on Sales [ROS] gained in five of the last eight quarters, with an average year-over-year change of +1523.11 percentage points.
  • The high point for year-over-year Return on Sales [ROS] in five years was fiscal Q4 2023 (a gain of 35848.59 percentage points); the low point was fiscal Q4 2022 (a drop of 41395.55 percentage points).
  • Per Business Quant data, the three fiscal quarters before Q2 2027 came in at -904.34% (Q1 2027), -3595.05% (Q4 2026) and -6450.83% (Q3 2026).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 PetVivo Holdings 3,096.39 Bn 3,096.39 Bn 196,075.00 -907.40%
2 Eli Lilly 1,202.70 Bn 1,176.32 Bn 20.46 Bn 34.46%
3 Johnson & Johnson 649.77 Bn 569.63 Bn 17.30 Bn 24.35%
4 AbbVie 507.00 Bn 475.00 Bn 13.12 Bn 36.01%
5 Merck 329.70 Bn 292.64 Bn 13.19 Bn 30.74%
6 Novartis Ag 291.91 Bn 265.14 Bn - -
7 Amgen 236.26 Bn 187.91 Bn 7.58 Bn 35.79%
8 Gilead Sciences 207.15 Bn 182.26 Bn 6.73 Bn 41.71%
9 Gsk 193.54 Bn 176.38 Bn - -
10 Vistagen Therapeutics 7.34 Mn -151.60 Mn - -7,925.36%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -7,925.36%
Jun 30, 2026 -904.34%
Mar 31, 2026 -3,595.05%
Dec 31, 2025 -6,450.83%
Sep 30, 2025 -7,772.48%
Jun 30, 2025 -6,477.05%
Mar 31, 2025 -11,517.08%
Dec 31, 2024 -6,461.54%
Sep 30, 2024 -7,774.32%
Jun 30, 2024 -14,441.67%
Mar 31, 2024 -6,926.22%
Dec 31, 2023 -1,918.25%
Sep 30, 2023 -2,260.00%
Jun 30, 2023 -3,499.00%
Mar 31, 2023 -6,953.98%
Dec 31, 2022 -5,425.83%
Sep 30, 2022 -1,958.49%
Jun 30, 2022 -6,376.36%
Mar 31, 2022 -42,802.56%
Dec 31, 2021 -2,943.85%
API Access

Vistagen Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=VTGN&period=max&api_key=YOUR_API_KEY